Merck (MRK) says the U.S. District Court in New Jersey has ruled against it in a patent infringement suit against Apotex Corp., saying its Nasonex patent would not be infringed by a competing product. The patent at issue covers mometasone furoate monohydrate, the active ingredient in Nasonex which Merck says provides exclusivity until April 3, 2018. Apotex is currently seeking FDA approval to sell a generic version. The drug giant will likely appeal the decision. Shares -0.2% AH.